Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.69 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24719004 | 1.00 | TLR8 (0.69) | TLR8TLR7KCNH2CYP2D6 | |
| SCHEMBL28691699 | 0.93 | CYP2D6 (0.65) | TLR8TLR7KCNH2CYP2D6 | |
| SCHEMBL21325603 | 0.93 | CYP2D6 (0.65) | TLR8TLR7KCNH2CYP2D6 | |
| SCHEMBL13975896 | 0.93 | CYP2D6 (0.65) | TLR8TLR7KCNH2CYP2D6 | |
| SCHEMBL21325649 | 0.87 | KCNH2 (0.85) | TLR8TLR7KCNH2CYP2D6 | |
| SCHEMBL13975563 | 0.87 | KCNH2 (0.85) | TLR8TLR7KCNH2CYP2D6 | |
| SCHEMBL21325602 | 0.87 | TLR8 (0.68) | TLR8TLR7KCNH2CYP2D6 | |
| SCHEMBL21325654 | 0.85 | TLR7 (0.65) | TLR8TLR7KCNH2CYP2D6 | |
| SCHEMBL24384569 | 0.83 | KCNH2 (0.55) | TLR8TLR7KCNH2CYP2D6 | |
| SCHEMBL22959029 | 0.83 | KCNH2 (0.55) | TLR8TLR7KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278964-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278964-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2023-09-07 | — | — | US | disclosed |
| EP-3986871-B1 | QUINAZOLINE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-06-07 | — | — | EP | disclosed |
| EP-4059924-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-21 | — | — | EP | disclosed |
| EP-3759083-B1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRUS INFECTIONS, CANCER OR ALLERGIES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2022-05-04 | — | — | EP | disclosed |
| CN-114008029-A | Quinazoline prodrugs for the treatment of viral infections and additional diseases | 爱尔兰詹森科学公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210040046-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimi (IE) | 2021-02-11 | — | — | US | disclosed |
| WO-2020255019-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND A QUINAZOLINE DERIVATIVE | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254473-A1 | QUINAZOLINE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020255039-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND QUINAZOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020255039-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND QUINAZOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| CN-111868040-A | 2, 4-diaminoquinazoline derivatives and medical uses thereof | 爱尔兰詹森科学公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019166532-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2019-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040046-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | HRH4, HRH3, HNMT | TLR8 400/4885TLR7 52/4885KCNH2 968/4885 |
| US-20230278964-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | QDPR, PADI2, PEPD | TLR8 584/4885TLR7 728/4885KCNH2 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.